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Abstract: Background: Antiretrovirals (ARVs) affect bone density and turnover, but their effect on
risk of fractures and osteonecrosis of the femoral head is less understood. We
investigated if exposure to ARVs increases the risk of both bone outcomes.
Methods: EuroSIDA participants were followed to assess fractures and osteonecrosis.
Poisson regression identified clinical, laboratory and demographic predictors of either
bone outcome. Ever, current and cumulative exposures to ARVs were assessed. .
Results: During 86118 PYFU among 11820 included persons (median age 41y, 75%
male, median baseline CD4 440/mm3, 70.4% virologically suppressed), there were
619 fractures (incidence/1000PYFU 7.2; 95%CI 6.6-7.7) and 89 osteonecrosis
(1.0;0.8-1.3). Older age, white race, lower BMI, IV drug use, lower baseline CD4, HCV-
coinfection, prior osteonecrosis, prior fracture, cardiovascular disease and recent non-
AIDS cancer (last 12 months) were associated with fractures. After adjustment,
persons who had ever used  Tenofovir Disoproxil Fumarate (TDF) (1.40; 1.15-1.70) or
who were currently on TDF (1.25; 1.05-1.49) had higher incidence of fractures. There
was no association between cumulative exposure to TDF and fractures (1.08/5y
exposure; 0.94-1.25). No other ARV was associated with fractures (all p>0.1). Risk of
osteonecrosis was associated with white race, lower nadir CD4, prior osteonecrosis,
prior fracture and prior AIDS. After mutual adjustment, no ARV was associated with
osteonecrosis.
Conclusions: In HIV infection, host factors, HIV-specific variables and co-morbidities
contribute to risk of fractures and osteonecrosis. Exposure to TDF, but not other ARVs,
was an independent risk factor for fractures.
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Authors’ response: We would like to thank the editor and reviewers for taking the 
time to read and comment on our paper. Your insightful comments and suggestions 
have improved our paper and are greatly appreciated.  
 
Please note that the font and color of supplemental figures 1 and 2, as well as 
Figure 2 and 4, have been formatted to match those of the remaining figures. No 
change in content has been made.  
   
Reviewer #1:  
 
"Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort" evaluates 
the rates and risk factors for fractures and osteonecrosis in the EuroSIDA cohort. The 
manuscript is well-written and important to the field given the large population studied and 
solid methods employed. I only have minor comments. 
 
1) In the methods section, the text refers to baseline CD4 and viral load. For me, this 
would refer to pre-ART values. However, in Supplemental Figure 1, it seems these values 
refer to baseline at around 1/1/2004 when bone data began to be routinely collected in 
EuroSIDA rather than pre-ART. This could be clarified in the text.  
 
Authors’ response: In the present study, we included persons aged >16 year with 
baseline data on CD4 counts and viral loads with prospective follow up. Baseline 
was defined as 1/1/2004, when routine prospective collection of data on fractures 
and osteonecrosis of the femoral head was initiated in EuroSIDA. This has been 
clarified in the methods section. 
 
In Table 1, as well as in supplemental table 1, the characteristics listed refer to the 
last visit for those with no bone event, or at last diagnosis of fracture or 
osteonecrosis. We believe that providing information at last visit is more clinically 
meaningful than listing variables measured at baseline, i.e. 1/1/2004. 
 
2) In Table 1, I would list the other race/ethnicities in the cohort.  
 
Authors’ response: the n(%) of participants with other race/ethnicities is now listed 
in Table 1. 
 
3) The ordering and naming of variables in the various tables is not consistent. The 
ordering and naming of variables should match the ordering and naming of the variables in 
Table 1 (e.g., age should not be listed almost last in Supplemental Table 1).  
 
Authors’ response: the ordering of variables in Supplemental Table 1 is now made 
consistent with Table 1.  
 
Supplemental Tables 2 and 3 list the variables entered into the multivariate models 
by predefined criteria. As such, the variables included in the final model for 
fractures are different from the variables included in the final model for 
osteonecrosis of the femoral head. We have now listed the variables in common in 
the same order.     
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paper_CID_v2.doc
 
4) It appears that risk group is associated with osteoporotic fracture according to 
Supplemental Table 1 but this is not listed in the text. 
 
Authors’ response: the p-value shown in supplemental table 1 refers to a global 
comparison across the different transmission risk groups. Despite the statistical 
significance, the frequencies of risk groups are not very different between 
participants with non-osteoporotic and osteoporotic fractures. We were  unsure as 
to whether this was clinically relevant but have  replaced, on the reviewer’s request, 
the statement “At last visit, participants with osteoporotic fractures were more likely 
to be older and to come from North Europe compared to participants with other 
fractures, but had otherwise similar demographic and clinical characteristics” with 
“At last visit, participants with osteoporotic fractures were more likely to be older, 
have sexually-acquired HIV and to come from North Europe compared to 
participants with other fractures, but had otherwise similar demographic and 
clinical characteristics”.  
 
Supplemental Table 1: Participant characteristics at last visit: non-osteoporotic 
versus osteoporotic fractures 
  Non-
osteoporotic 
Osteoporotic P-value  
Transmission 
risk 
MSM 170 (35.0) 52 (39.4) 0.030 
  IV drug use 141 (29.0) 27 (20.5)   
  Heterosexual 131 (27.0) 47 (35.6)   
 
 
5) "Data" is a plural word. Should read "there were not sufficient data" at end of page 8. 
 
Authors’ response: “There was not sufficient data” has been replaced with “There 
were not sufficient data” on page 8. 
 
6) It could be considered surprising that past TDF was associated with fracture in this 
study as studies in which individuals were switched off of TDF to other ARVs had 
significant increases in BMD. This finding is especially important now given that many 
individuals on TDF are now being switched to TAF. It might be good to highlight the results 
of switch studies off of TDF and how this study's results data suggest that there may still 
be residual bone abnormalities not fully captured by BMD data after the switch off of TDF.  
 
Authors’ response: Our data demonstrated that past and current exposure to TDF, 
but not cumulative exposure, is associated with fracture risk. We can confirm that 
participants with recent TDF discontinuations were not like current TDF users. 
Misclassification, therefore, is not a likely explanation. As shown in the Table below, 
the median (IQR) time since TDF discontinuation among those that have ever 
started TDF was shorter among those with bone outcomes when compared to those 
with no bone event. Only 46 fractures were reported among participants who had 
stopped TDF within one year before the occurrence of fractures.   
 
The reviewer’s point about treatment switch is important because it is known that 
discontinuation of TDF leads to increase in BMD that takes at least 1 year (switch to 
TAF and raltegravir data). Unfortunately, there are few participants currently using 
TAF and raltegravir-based regimens in EuroSIDA. Therefore, as mentioned in the 
discussion, we are underpowered to investigate this. We are very wary of over- 
interpreting our data and believe that a discussion on the effects of treatment swift 
on fracture/osteonecrosis risk would be beyond the scope of our investigation.     
 
 
 
 
 
 
 
 
Reviewer #2:  
 
Only minor edits would be formatting of Table 1 cells, and changing "homosexual" to MSM 
in Table.  
 
Authors’ response: “Homosexual” has been replaced with “MSM” in Table 1.  
 
However, given sex differences in osteoporosis and fracture risk, particularly at median 
age 47, Sex-stratified analyses should be conducted as well. If the findings are not 
Variable No bone 
event 
Fractures Osteonecrosis 
of the femoral 
head 
P-value* 
Ever on TDF; n (%) 7635 (64.1) 320 (64.7) 51 (69.9) 0.38 
On TDF; n (%) 5492 (46.5) 241 (48.7) 37 (50.7) 0.49 
Stopped TDF last 12 months; 
n(%) 
1703 (22.3) 46 (14.4) 8 (15.7) 0.0020 
Cumulative exposure TDF; 
median years (IQR) 
2.4 (0.0 – 6.3) 1.4 (0.0 – 
4.3) 
1.6 (0.0 – 4.6) <0.0001 
Cumulative exposure TDF 
among those ever started; 
median years (IQR) 
5.2 (2.7 – 7.8) 3.5 (1.6 – 
5.3) 
3.5 (1.4 – 6.6) <0.0001 
Time since stopping among 
those that have started; 
median years (IQR) 
3.2 (1.3 – 5.8) 1.6 (0.4 – 
3.3) 
1.4 (0.5 – 4.0) <0.0001 
substantially different between men and women, this could be simply stated in the results 
section, however these additional analyses should be performed. 
 
 
Authors’ response: Approximately 20% of EuroSIDA participants are female. As a 
result, power for sex-stratified analyses was low, particularly with respect to 
osteonecrosis of the femoral head. We ran each model by gender (as described in 
Supplemental tables 2 and 3), and compared the adjusted incidence rate ratios 
(aIRR) across gender. To reduce the impact of multiple testing, and mindful of the 
fact that this analysis was not planned a priori, we formally tested the interaction 
where there was a >2-fold difference in aIRRs for a given variable when comparing 
males and females. P-values for all interactions tested were not significant (i.e. > 
0.05). Therefore, findings were not substantially different between men and women. 
This has been included in the results section.  
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Summary:  We investigated the association of exposure to antiretroviral drugs with 
incident fractures and osteonecrosis of the femoral head in the EuroSIDA cohort. We 
demonstrated that past and current exposure to tenofovir disoproxil fumarate, but no other 
antiretroviral, was independently associated with higher incidence of fractures. After 
mutual adjustment, no antiretroviral was associated with osteonecrosis risk.  
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Abstract 
Background: Antiretrovirals (ARVs) affect bone density and turnover, but their effect on 
risk of fractures and osteonecrosis of the femoral head is less understood. We investigated 
if exposure to ARVs increases the risk of both bone outcomes.  
Methods: EuroSIDA participants were followed to assess fractures and osteonecrosis. 
Poisson regression identified clinical, laboratory and demographic predictors of either bone 
outcome. Ever, current and cumulative exposures to ARVs were assessed. . 
Results: During 86118 PYFU among 11820 included persons (median age 41y, 75% 
male, median baseline CD4 440/mm3, 70.4% virologically suppressed), there were 619 
fractures (incidence/1000PYFU 7.2; 95%CI 6.6-7.7) and 89 osteonecrosis (1.0;0.8-1.3). 
Older age, white race, lower BMI, IV drug use, lower baseline CD4, HCV-coinfection, prior 
osteonecrosis, prior fracture, cardiovascular disease and recent non-AIDS cancer (last 12 
months) were associated with fractures. After adjustment, persons who had ever used  
Tenofovir Disoproxil Fumarate (TDF) (1.40; 1.15-1.70) or who were currently on TDF 
(1.25; 1.05-1.49) had higher incidence of fractures. There was no association between 
cumulative exposure to TDF and fractures (1.08/5y exposure; 0.94-1.25). No other ARV 
was associated with fractures (all p>0.1). Risk of osteonecrosis was associated with white 
race, lower nadir CD4, prior osteonecrosis, prior fracture and prior AIDS. After mutual 
adjustment, no ARV was associated with osteonecrosis.  
Conclusions: In HIV infection, host factors, HIV-specific variables and co-morbidities 
contribute to risk of fractures and osteonecrosis. Exposure to TDF, but not other ARVs, 
was an independent risk factor for fractures.  
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Introduction 
 
    Fractures and osteonecrosis of the femoral head have emerged as important 
manifestations of bone disease during treated HIV infection. According to population-
based studies [1-3], HIV positive persons have a 1.5-3.0 greater risk of fractures than the 
general population. Osteonecrosis of the femoral head, although a rare bone disease, also 
disproportionally affects HIV positive persons. In the setting of HIV infection, it was 
estimated that osteonecrosis has a 100-fold excess risk when compared to the general 
population [4].    
    Initiation of antiretroviral therapy (ART) is associated with reduction in bone mineral 
density [5-7] and increases levels of markers of bone turnover [5,8]. The loss of bone 
mineral density following ART initiation is comparable in magnitude to that occurring during 
the perimenopausal period [9] and treatment with corticosteroids [10]. Changes in bone 
mineral density and turnover are observed irrespective of ART regimen, but tenofovir 
disoproxil fumarate (TDF)-containing regimens causes greater bone loss [6,11] whereas 
integrase inhibitor-based regimens may cause less bone loss [7]. However, the direct 
clinical consequences of this are yet to be determined because changes in bone mineral 
density are not perfect predictors of fracture risk [12] and the effect of ART exposure on 
the risk of fractures and osteonecrosis remain poorly understood. In a large HIV cohort, we 
set out to study the association of exposure to antiretroviral drugs with incident fractures 
and osteonecrosis of the femoral head and to determine factors independently associated 
with these two bone outcomes.     
 
 
Methods 
 
    The EuroSIDA study, a multinational prospective cohort of 20,854 HIV positive persons 
from across Europe, Argentina and Israel, has been documented in detail elsewhere [13]. 
Briefly, detailed information on clinical, virological and immunological parameters has been  
collected every 6 months with accurate recording of dates of AIDS-defining illnesses and 
serious non-AIDS-defining events, defined as cardiovascular disease, end-stage 
hepatic/renal disease, non-AIDS defining malignancies and pancreatitis [14]. Data quality 
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is assured by yearly monitoring visits to participating clinics and hospitals, when source 
documentation and dates of reported clinical events are cross-checked. In this study, we 
included persons aged >16 year with baseline data on CD4 counts and viral loads with 
prospective follow up. Baseline was defined as 1/1/2004, when routine prospective 
collection of data on fractures and osteonecrosis of the femoral head was initiated in 
EuroSIDA. Data on fractures and osteonecrosis was reported in follow up forms by the 
attending physician. Participating sites reporting no cases of fractures or osteonecrosis or 
with less than 100 person-years of follow up (PYFU) were excluded due to concerns about 
underreporting and data quality on bone outcomes.  
   Poisson regression using generalized estimating equations was used to identify clinical, 
laboratory and demographic factors associated with fractures and osteonecrosis of the 
femoral head.  More than one outcome per person was included accounting for correlation 
between and within included persons. Factors adjusted for were chosen on the basis of 
their epidemiological importance and biological plausibility and included baseline and time-
updated variables, as defined in a previous report [14]. To avoid model overfitting, factors 
with marginal associations (p<0.1) in univariate analyses were included in multivariate 
models. Nadir, baseline, and current CD4 counts, baseline and current viral load, as well 
as age, were all investigated as categorical and continuous variables with different 
transformations to identify the best fitting model. Clinical events were modelled as time-
updated covariates in different ways to identify the best fitting model, including non-
malignant AIDS events, AIDS-defining cancer, non-AIDS-defining malignancies and 
cardiovascular disease, and each of these as a recent event, i.e. occurring within the last 
12 months prior to the diagnosis of fracture or osteonecrosis. 
    Each antiretroviral was included in the best-fitting multivariate model to assess the effect 
of its exposure on the subsequent risk of fractures or osteonecrosis of the femoral head. 
Exposure to each antiretroviral was included as ever (yes/no), current (yes/no) and 
cumulative exposure. Antiretrovirals tested were zidovudine, didanosine, stavudine, 
lamivudine, emtricitabine, TDF, abacavir, nevirapine, efavirenz, saquinavir, ritonavir, 
lopinavir, indinavir, nelfinavir, atazanavir, ritonavir boosted lopinavir, and any other 
boosted protease inhibitors (grouped into one category). Antiretrovirals which remained 
independently associated with risk for fractures or osteonecrosis were subsequently 
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mutually adjusted for. It was not possible to assess other antiretrovirals such as integrase 
inhibitors owing to their short cumulative exposure among EuroSIDA participants.  
    We carried out secondary analyses restricted to osteoporotic fractures, grouped as 
fractures of the spine, arm, wrist and hip. Similar to other cohort studies without data on 
bone mineral density [15,16], our assumption was that fractures in these locations were 
more likely to be osteoporotic. Previous investigations reported an increased fracture risk 
among persons receiving TDF and boosted protease inhibitors concomitantly [16]. 
Therefore, we also investigated incidence rates of fractures according to three categories 
of current ART use: 1) current use of TDF but not boosted protease inhibitor; 2) current 
use of boosted protease inhibitor but not TDF; and 3) concomitant use of TDF and boosted 
protease inhibitor. Using category 3 as the comparator, we compared the incidence rate 
ratios of fractures across these 3 categories in models adjusted for demographics, HIV-
specific variables and co-morbidities.    
    Finally, patients presenting with severe Pneumocystis pneumonia are likely to be 
treated with adjuvant corticosteroids. We examined the association between past history of 
Pneumocystis pneumonia, as a proxy of corticosteroid exposure, and subsequent risk for 
fractures and osteonecrosis. 
 
Results 
 
    Of 20,854 EuroSIDA participants, 14,917 had prospective follow-up after baseline and 
were eligible for inclusion.  An additional 1,902 participants were excluded due to missing 
CD4 counts and/or viral load at baseline. 1,195 persons were excluded from sites with less 
than 100 PYFU or where no fractures or osteonecrosis were reported.  Thus, 11,820 
participants were eligible for final inclusion in the analyses (Supplemental Figure 1). 
    The odds of being excluded because of missing CD4 and viral load were higher in all 
HIV exposure groups compared to MSM, in all regions of Europe (except North) compared 
to South, and in those with hepatitis C virus (HCV) infection at baseline. The odds of being 
excluded due to missing CD4 and viral load were lower in those who had started ART, 
were older, had a later date of recruitment to EuroSIDA and in those with a higher nadir 
CD4 count. Participants excluded from small study sites or with no reported events were 
more likely to be older, female, non-white, non-MSM, and to be on ART and have a later 
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date of enrolment to EuroSIDA. Table 1 summarizes participant characteristics at the time 
of diagnosis of fractures or osteonecrosis and at last visit for those without either outcome. 
There was a higher proportion of fractures and osteonecrosis among IV drug users and 
HCV coinfected persons. Persons with a bone outcome tended to have a lower current 
CD4 count than those without an event. Persons with osteonecrosis had significantly 
higher levels of triglycerides. There were no differences between participants with and 
without a bone outcome in terms of chronic kidney disease, estimated glomerular filtration 
rate (eGFR) and vitamin D levels (Table 1). 
    Among 11,820 included participants during 86,118 PYFU, 496 persons had 619 incident 
fractures (incidence rate [IR]/1,000 PYFU, 95% confidence interval [CI]: 7.2, 6.6-7.7) and 
73 persons developed 89 cases of osteonecrosis of the femoral head (IR: 1.0, 0.8-1.3) 
(Supplemental Figure 1).  
    Considering fractures with a known site, the most frequent were fractures of the leg, 
followed by arm, ribs and foot. 132 fractures (21.3%) were classified as osteoporotic 
(Supplemental Figure 2). At last visit, participants with osteoporotic fractures were more 
likely to be older, have sexually-acquired HIV and to come from North Europe compared to 
participants with other fractures, but had otherwise similar demographic and clinical 
characteristics (Supplemental Table 1). Information regarding fracture site could not be 
ascertained for 202 fractures (32.6%).  Participants with fractures of unknown sites were 
more likely to be female, to be ART naïve at study entry, have a prior AIDS diagnosis and 
have a higher current CD4 count when compared to participants with known fracture sites.  
    In analyses stratified by time-updated CD4 count, the crude incidence of fractures 
decreased as CD4 counts increased (P<0.0001). On the other hand, the incidence of 
osteonecrosis did not vary significantly across different CD4 count strata (P=0.055).   
    Univariate and multivariate associations between covariates and risk for fractures and 
osteonecrosis are detailed in supplemental Tables 2 and 3. After adjustment, an increased 
risk of incident fractures was independently associated with older age, lower BMI, IV drug 
use, HCV co-infection, prior fracture, prior osteonecrosis of the femoral head, a recent 
non-AIDS-defining malignancy and recent cardiovascular disease (Figure 1). Another 
independent predictor of fractures was origin, with participants from Northern and Central 
Europe at significantly increased risk (Supplemental Table 2). Race other than white and a 
8 
 
higher current CD4 count were associated with lower fracture risk (Figure 1). Findings 
were not substantially different between men and women (data not shown). 
    With respect to osteonecrosis of the femoral head, a prior history of osteonecrosis, 
fractures and AIDS-defining illnesses (both opportunistic infections and AIDS-defining 
cancers) was independently associated with increased risk (Figure 1). Race other than 
white and a higher baseline CD4 count were independently associated with a lower risk for 
osteonecrosis (Figure 1)    
    In univariate analyses, ever, current and cumulative exposure to TDF was associated 
with increased fracture risk. Crude incidence rates are depicted in Figure 2. Whether 
modelled as ever, current or cumulative, no association between exposure to any of the 
other investigated antiretrovirals and fracture risk was observed (data not shown). After 
adjustment (Figure 3), persons who had ever used TDF (adjusted incidence rate ratio 
[aIRR], 95% CI: 1.40, 1.15-1.70 p=0.0008) or who were currently receiving TDF (aIRR 
1.25, 1.05-1.49, p=0.012) had a significantly increased incidence of fractures. The 
association of fracture risk with cumulative exposure to TDF did not retain statistical 
significance after adjustment (aIRR 1.08, 0.94-1.25, per 5 years of additional exposure, 
p=0.27). In analyses restricted to osteoporotic fractures, no significant association was 
seen with ever, current or cumulative exposure to TDF (Figure 3).  
    In adjusted analyses to investigate incidence rate ratios of fractures for categories of 
current ART use stratified according to TDF and boosted protease inhibitor, we found no 
difference in fracture risk in those receiving TDF but not boosted protease inhibitor (aIRR, 
95% CI: 0.91, 0.71-1.18 p=0.49) and in those receiving boosted protease inhibitor but not 
TDF (aIRR, 95% CI: 0.87, 0.65-1.03 p=0.09) when compared to persons simultaneously 
receiving TDF and boosted protease inhibitor.  
    After adjustment, persons who had ever used didanosine, indinavir, saquinavir, ritonavir 
boosted lopinavir, or TDF, had increased incidence rates of osteonecrosis of the femoral 
head (Figure 4), although the confidence intervals were quite wide reflecting the lower 
number of outcomes. However, when these antiretrovirals were mutually adjusted for, 
there was no significant relationship between exposure to any of them and osteonecrosis 
risk (Figure 4), although all of them were associated with a non-significant increased risk.  
There was no association between cumulative exposure to any of these antiretrovirals and 
osteonecrosis. Current use of ritonavir boosted lopinavir or TDF was not associated with 
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an increased incidence of osteonecrosis of the femoral head. There were not sufficient 
data to examine current exposure to didanosine, indinavir or saquinavir as these 
antiretrovirals are no longer commonly used. Whether assessed as ever, current or 
cumulative, exposure to none of the other investigated antiretrovirals was associated with 
osteonecrosis of the femoral head.  
    Pneumocystis pneumonia was associated with both bone outcomes in univariate 
analyses (IRR, 95% CI: 1.35, 1.02-1.79 p= 0.039, for fractures; and 2.61, 1.41-4.83 
p=0.0022, for osteonecrosis); this association, however, was no longer significant after 
adjustment (adjusted IRR, 95% CI: 0.99, 0.72-1.36 p=0.94, for fractures; and 1.27, 0.63-
2.49 p=0.51, for osteonecrosis).      
 
Discussion 
    In a large international HIV cohort involving participants receiving standard of care, we 
report that fractures and osteonecrosis of the femoral head are common bone outcomes. 
The risk of fractures and osteonecrosis seems to be determined by combination of host 
factors, HIV-specific variables and co-morbidities. We demonstrated that past and current 
exposure to TDF, but no other antiretroviral, was independently associated with higher 
incidence of fractures. Persons who had ever used didanosine, indinavir, saquinavir, 
ritonavir boosted lopinavir, or TDF, had higher risk of osteonecrosis of the femoral head, 
but this association was no longer significant after mutual adjustment. 
    Consistent with previous reports, we found that older age [1,16], white race [1,16], lower 
current CD4 count [17,18], IV drug use [1,19] and HCV co-infection [1,19] were 
independent predictors of fracture risk. We found that history of prior osteonecrosis, a 
recent non AIDS-defining cancer and recent cardiovascular disease were also associated 
with subsequent risk of fracture. The association with cancer and cardiovascular disease 
may reflect bone loss caused by co-morbidity treatments such as chemotherapy. It is also 
possible that a shared pathophysiological mechanism may lead to an increased risk of 
fractures and co-morbidities during HIV infection [20].  
    Exposure to TDF was linked to an increased risk of fractures in our study. Although 
smaller studies failed to find this association [15,17], our results are in overall agreement 
with larger and more recent cohort studies [1,16]. The question as to how TDF directly 
causes bone loss remains unanswered. Proximal tubular toxicity leading to phosphate 
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wasting and enhanced bone turnover is a possible mechanism [21]. However, proximal 
tubular renal dysfunction and enhanced bone turnover do not necessarily coexist [22]. In 
our study, there was no difference in renal function, as measured by eGFR, between those 
with and without a bone event. This suggests that TDF-associated bone toxicity and 
nephrotoxicity may be determined by different mechanisms. However, we did not compare 
proteinuria, glycosuria and phosphaturia among participants with and without fractures and 
it is possible that proximal tubular dysfunction among those receiving TDF may have 
preceded measurable changes in eGFR.     
    Of note, we found that past and current exposure to TDF, but not cumulative exposure, 
was associated with a significantly increased risk of fractures. A possible explanation is the 
fact that decreases in bone mineral density and increases in markers of bone turnover are 
steepest in the first one or two years following ART initiation [5,6,23]. After a critical initial 
period, abnormalities in bone metabolism caused by ART may not be progressive [23]. 
Consistent with this, the risk of fractures was found to be highest during the first two years 
of ART [15] to then continue to increase less steeply. We found an aIRR for fracture risk of 
1.08 per 5 years of additional exposure to TDF. Although this was not statistically 
significant we cannot exclude the possibility of 8% yearly cumulative risk of fractures with 
TDF exposure.   
    The pathophysiology of osteonecrosis of the femoral head is poorly understood [24], but 
the primary mechanism is vascular occlusion leading to bone hypoxia and necrosis [25]. 
Increased inflammation and coagulation, as demonstrated by elevated levels of D-dimer 
and C-reactive protein, were also linked to osteonecrosis risk [26]. In accordance with 
other studies, we found that history of ADS-defining conditions and lower CD4 counts [27-
29] are associated with increased risk of osteonecrosis. White race and history of prior 
fractures and prior osteonecrosis were factors independently associated with incident 
osteonecrosis. These same factors predicted fracture risk; which may be potentially 
explained by a common mechanism underlying the excess risk of osteoporosis and 
osteonecrosis in the setting of HIV infection [30]. However, whereas osteoporotic fractures 
are the clinical manifestation of low bone mineral density, osteonecrosis has a different 
pathogenesis involving impaired circulation [25].   
    We found past exposure to didanosine, indinavir, saquinavir, ritonavir boosted lopinavir, 
or TDF to be independently associated with osteonecrosis risk. However, after mutual 
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adjustment, these associations were attenuated and became no longer significant. A 
possible association between protease inhibitors and osteonecrosis risk was reported in a 
meta-analysis of case-control studies [31]. Our study was more methodologically sound 
because we had detailed time-updated information on exposure to individual antiretrovirals 
and performed mutual adjustment. However, we cannot exclude the possibility that ART 
exposure may have a small effect on osteonecrosis risk. If this was the case, the effect of 
individual antiretrovirals may have been too weak to be identified concomitantly with other 
bone-active drugs [32]. 
    Our study had important limitations. First, we had no data on bone mineral density and 
bone events were not centrally adjudicated. Therefore, we could not confirm the 
osteoporotic nature of fractures. Information on anatomic sites was unavailable for a 
sizeable proportion of fractures. Magnetic resonance imaging was not systematically 
performed to diagnose osteonecrosis of the femoral head; the occurrence of bone events 
was confirmed during monitoring visits only. Second, we had no data on alcohol use and 
use of corticosteroids, megestrol acetate or testosterone. Exposure to these drugs has 
been previously reported in relation to risk of fractures and osteonecrosis [29,33,34]. We 
investigated previous history of Pneumocystis pneumonia as a proxy for corticosteroid 
exposure and found no significant association in adjusted analyses.  Third, ART evolves 
quickly and it is unclear whether our findings are generalizable to tenofovir alafenamide 
(TAF)-  or integrase inhibitor-based ART regimens.  
    To conclude, fractures and osteonecrosis of the femoral head are manifestations of 
bone disease among HIV positive persons receiving ARV treatment. Host factors, HIV-
specific variables and co-morbidities contribute to the risk of these bone events. Past and 
current exposure to TDF, but not cumulative exposure, is independently associated with 
fracture risk.  Our data supports cautious use of TDF among HIV positive persons at 
fracture risk initiating ART as recommended by current guidelines [35] and expert panels 
[36]. Individual antiretrovirals are not significantly associated with risk of osteonecrosis of 
the femoral head after mutual adjustment. However, we could not exclude a small effect of 
ART exposure on osteonecrosis risk. Larger studies are warranted to clarify this.           
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Tables 
Table 1: Characteristics at last visit for those with no bone event, or at last 
diagnosis of fracture or osteonecrosis 
Supplemental Table 1: Participant characteristics at last visit: non-osteoporotic 
versus osteoporotic fractures. 
Supplemental Table 2:  Univariate and multivariate factors associated with any 
fracture. 
Supplemental Table 3: Univariate and multivariate factors associated with 
osteonecrosis of the femoral head. 
 
Figures 
Figure 1: Factors independently associated with fractures and osteonecrosis of the 
femoral head.  
aIRR: adjusted incidence rate ratio. Models adjusted for depicted covariates plus 
calendar year and region. Only covariates significant (p<0.1) in univariate analyses 
were included in multivariate models to avoid overfitting.  
1 not significant for osteonecrosis in univariate analysis and hence not included in 
multivariate model for osteonecrosis 
2 not significant for fractures in univariate analysis and hence not included in 
multivariate model for fractures 
  
Figure 2: Crude incidence of fractures. TDF use. 
CI: confidence interval, PYFU: person-years of follow up, TDF: tenofovir disoproxil 
fumarate. 
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Figure 3: Effect of TDF exposure on risk of any fracture and of osteoporotic 
fractures a. 
a grouped as fractures of the spine, arm, wrist and hip 
b adjusted for demographics, HIV-specific variables and co-morbidities. 
 
Figure 4: Relationship between antiretroviral drugs and osteonecrosis. 
ARV: antiretroviral, DDI: didanosine, IDV: indinavir, LPV/r: ritonavir boosted 
lopinavir, SQV: saquinavir, TDF : tenofovir disoproxil fumarate.   
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Table 1:  Characteristics at last visit for those with no bone event, or at last diagnosis of fracture or 
osteonecrosis 
Variable No bone event Fractures Osteonecrosis of 
the femoral head 
P-value* 
Overall 11266 (95.2) 496 (4.2) 73 (0.6)  
Demographics 
n(%)/Median (IQR) 
    
Male gender 8460 (75.4) 357 (72.1) 58 (76.5) 0.22 
Age (years) 49 (42,56) 50 (44,59) 47 (43,56) 0.0089 
HIV transmission group      
   MSM 4800 (42.6) 180 (36.4) 35 (47.9) 0.0032 
   Heterosexual 3475 (30.9) 150 (30.3) 17 (23.3)  
   IDU 2156 (19.1) 130 (26.3) 14 (23.3)  
White ethnicity 9702 (86.1) 445 (89.9) 68 (93.1) 0.013 
Asian 207 (1.8) 9 (1.6) 2 (2.7)  
Black 638 (5.7) 21 (4.2) 1 (1.4)  
Other 719 (6.4) 21 (4.2) 2 (2.7)  
Body Mass Index (Kg/m2)     
    ≤ 18 926 (9.3) 64 (13.9) 10 (14.9) 0.0006 
    18-30 4248 (42.8) 214 (46.4) 29 (43.3)  
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     >30 4760 (47.9) 183 (39.7) 28 (41.8)  
HIV-specific variables 
n(%)/Median (IQR) 
    
On ART 10857 (89.1) 486 (97.0) 73 (100) 0.20 
CD4 cells/mm
3
 540 (340,749) 450 (332,658) 468 (328,621) 0.0004 
Nadir CD4 cells/mm
3
 176 (72,290) 120 (50,230) 90 (28,168) <0.0001 
HIV RNA <500 cp/ml 10032 (89.1) 441 (89.1) 70 (95.9) 0.17 
Co-morbidities n(%) 
    
HCV positive 2805 (24.9) 157 (31.7) 18 (24.7) 0.012 
Current smoking 3248 (28.8) 188 (38.0) 31 (42.5) <0.0001 
Prior osteonecrosis 43 (0.4) 14 (2.8) 20 (27.4) <0.0001 
Prior fracture 202 (1.8) 79 (16.0) 6 (8.2) <0.0001 
Prior AIDS 3526 (31.6) 188 (38.0) 43 (58.9) < 0.0001 
Prior AIDS (not cancer) 3114 (27.6) 176 (35.6) 38 (52.1) <0.0001 
Prior AIDS (cancer) 743 (6.6) 30 (6.1) 14 (19.2) <0.0001 
Prior non-AIDS cancer  1570 (13.9) 80 (16.2) 11 (15.1) 0.37 
Prior cardiovascular disease 229 (2.0) 21 (4.2) 3 (4.1) <0.0001 
Recent AIDS event 
a
 217 (1.9) 8 (1.6) 0 (0) 0.43 
Recent AIDS (not cancer) 
a
 172 (1.5) 7 (1.4) 0 (0) 0.58 
Recent AIDS cancer 
a
 55 (0.5) 1 (0.2) 0 (0) 0.25 
Recent non-AIDS cancer 
a
 403 (3.6) 23 (4.7) 6 (8.2) 0.052 
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Recent cardiovascular 
disease 
a
 
10 (0.1) 4 (0.8) 0 (0) <0.0001 
Chronic kidney disease 
b
 583 (5.3) 26 (5.6) 5 (7.5) 0.71 
eGFR 
c
 mL/min/1.73 m
2
 
Median (IQR)  
95 (80,106) 96 (79,106) 94 (75,106) 0.58 
Vitamin D 
d
 ng/mL 
Median (IQR) 
37 (22,65) 35 (15,83) 31 (9,40) 0.26 
Total cholesterol mg/dL 
Median (IQR)e 
191 (162  -223) 193 (166 – 223) 196 (170 – 228) 0.43 
Triglycerides mg/dL 
Median (IQR)f 
136 (92 – 208) 139 (97 – 208) 181 (108 – 328) 0.0025 
*global p-values for comparing across the three groups 
(a) Occurring in the last 12 months prior to the diagnosis of fracture or osteonecrosis of the femoral head. 
(b) chronic kidney disease at any time before last visit or event date; defined as confirmed (> 3 months apart) 
eGFR < 60 for those with first eGFR > 60, or 25% decline where baseline eGFR< 60.  eGFRs were 
calculated using CKD-EPI formula. 
(c)  eGFR was available for 11536 (97.5%); 11003 (97.7%) for those with no events, 466 (94.1%) for those 
with any fracture and 67 (91.8%) for those with osteonecrosis of the femoral head (p<0.0001).  
(d)  Data available for 3291 (27.8%) overall, 3210 (28.5%) for those with no events, 71 (14.3%) for those with 
fractures and 10 (13.7%) of those with osteonecrosis of the femoral head (p<0.0001). 
(e) Data available for 11687 (98.9%) overall; 11122 (98.7%) for those with no events, 492 (99.4%) for those 
with fractures and 73 (100%) of those with osteonecrosis of the femoral head (p=0.26) 
(f) Data available for 11365 (96.2%) overall; 10813 (96.0%) for those with no events, 482 (97.4%) for those 
with fractures and 70 (95.9%) of those with osteonecrosis of the femoral head (p=0.26) 
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Supplemental Table 1: Participant characteristics at last visit: non-osteoporotic versus 
osteoporotic fractures 
    Non-osteoporotic Osteoporotic P-value  
Overall 486 (78.6) 132 (21.4)   
Characteristic  
n(%)/Median (IQR) 
   
Gender Male 357 (73.5) 91 (68.9) 0.30 
Age (years)   49 (44,59) 52 (46,60) 0.021 
HIV transmission 
group 
MSM 170 (35.0) 52 (39.4) 0.030 
  IV drug use 141 (29.0) 27 (20.5)   
  Heterosexual 131 (27.0) 47 (35.6)   
Race White 436 (89.7) 123 (93.2) 0.23 
Region North Europe 211 (43.4) 72 (54.6) 0.0006 
  Central and 
Eastern 
Europe 
47 (9.7) 22 (16.7)   
On ART    468 (96.3) 129 (97.7) 0.42 
CD4  cells/mm
3
 
  441 (311,663) 454 (340,651) 0.62 
Viral load < 500 
copies/mL 
  427 (87.9) 119 (90.2) 0.47 
HBV Pos 25 (5.1) 5 (3.8) 0.61  
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HCV Pos 166 (34.2) 39 (29.6) 0.57 
Recent AIDS a 7 (1.4) 4 (3.0) 0.22 
Chronic kidney 
disease b 
  28 (5.8) 3 (2.2) 0.10 
eGFR c   97 (80,106) 95 (77,100) 0.33 
Vitamin D d   33 (11,72) 34 (23,84) 0.42 
(a) in last 12 months prior to diagnosis of fractures  
(b) chronic kidney disease at any time before last visit or event date; defined as confirmed (> 3 
months apart) eGFR < 60 for those with first eGFR > 60, or 25% decline where baseline eGFR< 
60.  
(c) eGFR was available for 455 (93.6%) for those with non-osteoporotic fractures and 127 (96.2%) 
for those with osteoporotic fractures (p=0.26). eGFRs were calculated using CKD-EPI formula. 
(d) Data available for 64 (13.2%) for those with non-osteoporotic fractures and 15 (11.4%) for those 
with osteoporotic fractures (p=0.58).    
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Supplemental Table 2: Univariate and multivariate factors associated with any fracture 
  Univariate Multivariate 
  IRR 95% CI P IRR 95% CI P 
Age /10 yrs 1.42 1.31 – 1.54 <0.0001 1.39 1.26 – 1.53 <0.0001 
HIV transmission 
group 
IDU 1.75 1.39 – 2.14 <0.0001 1.58 1.18 – 2.12 0.0021 
 Other 1.00 - - 1.00 - - 
Race White 1.00 - - 1.00 - - 
 Other 0.67 0.50 – 0.90 0.0073 0.64 0.47 – 0.88 0.0056 
BMI <18 1.69 1.27 – 2.26 0.0004 1.51 1.14 – 1.99 0.0036 
 18-30 1.00 - - 1.00 - - 
 >30 0.90 0.73 – 1.10 0.30 0.91 0.74 – 1.11 0.36 
 unknown 0.65 0.44 – 0.98 0.039 0.79 0.52 – 1.18 0.25 
CD4* /doubling 0.73 0.64 – 0.83 <0.0001 0.80 0.69 – 0.92 0.0014 
Nadir CD4 /doubling 0.71 0.63 – 0.80 <0.0001 0.92 0.79 – 1.07 0.25 
Baseline <500 1.00 - - 1.00 - - 
Viral Load 500-100k 0.68 0.53 – 0.87 0.0019 0.84 0.66 – 1.08 0.17 
 >100k 1.06 0.70 – 1.60 0.78 1.05 0.71 – 1.55 0.81 
Region S 1.00 - - 1.00 - - 
 N 1.80 1.32 – 2.47 0.0003 1.83 1.32 – 2.52 0.0003 
 C 3.29 2.47 – 4.40 <0.0001 3.63 2.68 – 4.91 <0.0001 
 CE 1.58 1.12 – 2.22 0.0092 1.60 1.13 – 2.28 0.0087 
Year of follow up* <2006 1.00 - - 1.00 - - 
 07-09 1.58 1.22 – 2.04 0.0005 1.50 1.16 – 1.94 0.0020 
 10-12 1.75 1.36 – 2.25 <0.0001 1.56 1.20 – 2.02 0.0007 
 >2012 1.28 0.95 – 1.72 0.10 1.09 0.80 – 1.48 0.58 
HCV* Neg 1.00 - - 1.00 - - 
 Pos 1.70 1.39 – 2.09 <0.0001 1.59 1.20 – 2.11 0.0013 
 Unknown 0.68 0.45 – 1.03 0.068 0.81 0.53 – 1.22 0.31 
29 
 
Smoking Never 1.00 - - 1.00 - - 
 Current 1.28 1.01 – 1.61 0.040 1.09 0.86 – 1.38 0.47 
 Past 0.93 0.70 – 1.29 0.65 0.80 0.58 – 1.11 0.18 
 Unknown 0.90 0.70 – 1.15 0.38 0.72 0.57 – 0.92 0.0083 
 Arg 0.68 0.35 – 1.41 0.30 0.88 0.42 – 1.82 0.72 
Osteonecrosis* No 1.00 - - 1.00 - - 
Yes 4.69 2.95 – 7.46 <0.0001 3.19 1.91 – 5.31 <0.0001 
Prior 
Fracture 
No 1.00 - - 1.00 - - 
Yes 5.24 3.45 – 7.96 <0.0001 3.89 2.62 – 5.77 <0.0001 
AIDS (not 
cancer)* 
 1.46 1.20 – 1.77 <0.0001 1.13 0.92 – 1.38 0.25 
Recent non-
AIDS-defining 
malignancy* 
 3.10 2.11 – 4.57 <0.0001 1.88 1.26 – 2.80 0.0018 
Recent 
cardiovascular 
disease* 
 9.56 3.68 – 
24.82 
<0.0001 6.03 2.28 – 15.95 0.0003 
All factors fixed at baseline, except *, which were time-updated 
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Supplemental Table 3: Univariate and multivariate factors associated with osteonecrosis of the 
femoral head 
  Univariate Multivariate 
  IRR 95% CI P IRR 95% CI P 
Age /10 yrs 1.19 0.99 – 1.43 0.068 1.07 0.87 – 1.31 0.54 
Race White 1.00 - - 1.00 - - 
 Other 0.38 0.15 – 0.95 0.038 0.28 0.11 – 0.76 0.012 
Nadir CD4 /doubling 0.52 0.36 – 0.75 0.0005 0.71 0.51 – 1.01 0.054 
Prior 
osteonecrosis 
No 1.00 - - 1.00 - - 
Yes 20.82 10.32 – 
41.99 
<0.0001 14.95 6.96 – 32.15 <0.0001 
Prior fracture* No 1.00 - - 1.00 - - 
 Yes 4.26 2.13 – 8.50 <0.0001 3.12 1.50 – 6.49 0.0023 
AIDS (not 
cancer)* 
 2.92 1.78 – 4.80 <0.0001 2.13 1.27 – 3.57 0.0043 
AIDS-defining 
cancer* 
 3.57 1.96 – 6.50 <0.0001 2.69 1.48 – 4.89 0.0012 
Non-AIDS-
defining 
malignancies* 
 2.00 1.03 – 3.91 0.042 1.33 0.65 – 2.69 0.43 
All factors fixed at baseline, except *, which were time-updated 
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Summary:  We investigated the association of exposure to antiretroviral drugs with 
incident fractures and osteonecrosis of the femoral head in the EuroSIDA cohort. We 
demonstrated that past and current exposure to tenofovir disoproxil fumarate, but no other 
antiretroviral, was independently associated with higher incidence of fractures. After 
mutual adjustment, no antiretroviral was associated with osteonecrosis risk.  
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Abstract 
Background: Antiretrovirals (ARVs) affect bone density and turnover, but their effect on 
risk of fractures and osteonecrosis of the femoral head is less understood. We investigated 
if exposure to ARVs increases the risk of both bone outcomes.  
Methods: EuroSIDA participants were followed to assess fractures and osteonecrosis. 
Poisson regression identified clinical, laboratory and demographic predictors of either bone 
outcome. Ever, current and cumulative exposures to ARVs were assessed. . 
Results: During 86118 PYFU among 11820 included persons (median age 41y, 75% 
male, median baseline CD4 440/mm3, 70.4% virologically suppressed), there were 619 
fractures (incidence/1000PYFU 7.2; 95%CI 6.6-7.7) and 89 osteonecrosis (1.0;0.8-1.3). 
Older age, white race, lower BMI, IV drug use, lower baseline CD4, HCV-coinfection, prior 
osteonecrosis, prior fracture, cardiovascular disease and recent non-AIDS cancer (last 12 
months) were associated with fractures. After adjustment, persons who had ever used  
Tenofovir Disoproxil Fumarate (TDF) (1.40; 1.15-1.70) or who were currently on TDF 
(1.25; 1.05-1.49) had higher incidence of fractures. There was no association between 
cumulative exposure to TDF and fractures (1.08/5y exposure; 0.94-1.25). No other ARV 
was associated with fractures (all p>0.1). Risk of osteonecrosis was associated with white 
race, lower nadir CD4, prior osteonecrosis, prior fracture and prior AIDS. After mutual 
adjustment, no ARV was associated with osteonecrosis.  
Conclusions: In HIV infection, host factors, HIV-specific variables and co-morbidities 
contribute to risk of fractures and osteonecrosis. Exposure to TDF, but not other ARVs, 
was an independent risk factor for fractures.  
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Introduction 
 
    Fractures and osteonecrosis of the femoral head have emerged as important 
manifestations of bone disease during treated HIV infection. According to population-
based studies [1-3], HIV positive persons have a 1.5-3.0 greater risk of fractures than the 
general population. Osteonecrosis of the femoral head, although a rare bone disease, also 
disproportionally affects HIV positive persons. In the setting of HIV infection, it was 
estimated that osteonecrosis has a 100-fold excess risk when compared to the general 
population [4].    
    Initiation of antiretroviral therapy (ART) is associated with reduction in bone mineral 
density [5-7] and increases levels of markers of bone turnover [5,8]. The loss of bone 
mineral density following ART initiation is comparable in magnitude to that occurring during 
the perimenopausal period [9] and treatment with corticosteroids [10]. Changes in bone 
mineral density and turnover are observed irrespective of ART regimen, but tenofovir 
disoproxil fumarate (TDF)-containing regimens causes greater bone loss [6,11] whereas 
integrase inhibitor-based regimens may cause less bone loss [7]. However, the direct 
clinical consequences of this are yet to be determined because changes in bone mineral 
density are not perfect predictors of fracture risk [12] and the effect of ART exposure on 
the risk of fractures and osteonecrosis remain poorly understood. In a large HIV cohort, we 
set out to study the association of exposure to antiretroviral drugs with incident fractures 
and osteonecrosis of the femoral head and to determine factors independently associated 
with these two bone outcomes.     
 
 
Methods 
 
    The EuroSIDA study, a multinational prospective cohort of 20,854 HIV positive persons 
from across Europe, Argentina and Israel, has been documented in detail elsewhere [13]. 
Briefly, detailed information on clinical, virological and immunological parameters has been  
collected every 6 months with accurate recording of dates of AIDS-defining illnesses and 
serious non-AIDS-defining events, defined as cardiovascular disease, end-stage 
hepatic/renal disease, non-AIDS defining malignancies and pancreatitis [14]. Data quality 
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is assured by yearly monitoring visits to participating clinics and hospitals, when source 
documentation and dates of reported clinical events are cross-checked. In this study, we 
included persons aged >16 year with baseline data on CD4 counts and viral loads with 
prospective follow up. Baseline was defined as 1/1/2004, when routine prospective 
collection of data on fractures and osteonecrosis of the femoral head was initiated in 
EuroSIDA. Data on fractures and osteonecrosis was reported in follow up forms by the 
attending physician. Participating sites reporting no cases of fractures or osteonecrosis or 
with less than 100 person-years of follow up (PYFU) were excluded due to concerns about 
underreporting and data quality on bone outcomes.  
   Poisson regression using generalized estimating equations was used to identify clinical, 
laboratory and demographic factors associated with fractures and osteonecrosis of the 
femoral head.  More than one outcome per person was included accounting for correlation 
between and within included persons. Factors adjusted for were chosen on the basis of 
their epidemiological importance and biological plausibility and included baseline and time-
updated variables, as defined in a previous report [14]. To avoid model overfitting, factors 
with marginal associations (p<0.1) in univariate analyses were included in multivariate 
models. Nadir, baseline, and current CD4 counts, baseline and current viral load, as well 
as age, were all investigated as categorical and continuous variables with different 
transformations to identify the best fitting model. Clinical events were modelled as time-
updated covariates in different ways to identify the best fitting model, including non-
malignant AIDS events, AIDS-defining cancer, non-AIDS-defining malignancies and 
cardiovascular disease, and each of these as a recent event, i.e. occurring within the last 
12 months prior to the diagnosis of fracture or osteonecrosis. 
    Each antiretroviral was included in the best-fitting multivariate model to assess the effect 
of its exposure on the subsequent risk of fractures or osteonecrosis of the femoral head. 
Exposure to each antiretroviral was included as ever (yes/no), current (yes/no) and 
cumulative exposure. Antiretrovirals tested were zidovudine, didanosine, stavudine, 
lamivudine, emtricitabine, TDF, abacavir, nevirapine, efavirenz, saquinavir, ritonavir, 
lopinavir, indinavir, nelfinavir, atazanavir, ritonavir boosted lopinavir, and any other 
boosted protease inhibitors (grouped into one category). Antiretrovirals which remained 
independently associated with risk for fractures or osteonecrosis were subsequently 
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mutually adjusted for. It was not possible to assess other antiretrovirals such as integrase 
inhibitors owing to their short cumulative exposure among EuroSIDA participants.  
    We carried out secondary analyses restricted to osteoporotic fractures, grouped as 
fractures of the spine, arm, wrist and hip. Similar to other cohort studies without data on 
bone mineral density [15,16], our assumption was that fractures in these locations were 
more likely to be osteoporotic. Previous investigations reported an increased fracture risk 
among persons receiving TDF and boosted protease inhibitors concomitantly [16]. 
Therefore, we also investigated incidence rates of fractures according to three categories 
of current ART use: 1) current use of TDF but not boosted protease inhibitor; 2) current 
use of boosted protease inhibitor but not TDF; and 3) concomitant use of TDF and boosted 
protease inhibitor. Using category 3 as the comparator, we compared the incidence rate 
ratios of fractures across these 3 categories in models adjusted for demographics, HIV-
specific variables and co-morbidities.    
    Finally, patients presenting with severe Pneumocystis pneumonia are likely to be 
treated with adjuvant corticosteroids. We examined the association between past history of 
Pneumocystis pneumonia, as a proxy of corticosteroid exposure, and subsequent risk for 
fractures and osteonecrosis. 
 
Results 
 
    Of 20,854 EuroSIDA participants, 14,917 had prospective follow-up after baseline and 
were eligible for inclusion.  An additional 1,902 participants were excluded due to missing 
CD4 counts and/or viral load at baseline. 1,195 persons were excluded from sites with less 
than 100 PYFU or where no fractures or osteonecrosis were reported.  Thus, 11,820 
participants were eligible for final inclusion in the analyses (Supplemental Figure 1). 
    The odds of being excluded because of missing CD4 and viral load were higher in all 
HIV exposure groups compared to MSM, in all regions of Europe (except North) compared 
to South, and in those with hepatitis C virus (HCV) infection at baseline. The odds of being 
excluded due to missing CD4 and viral load were lower in those who had started ART, 
were older, had a later date of recruitment to EuroSIDA and in those with a higher nadir 
CD4 count. Participants excluded from small study sites or with no reported events were 
more likely to be older, female, non-white, non-MSM, and to be on ART and have a later 
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date of enrolment to EuroSIDA. Table 1 summarizes participant characteristics at the time 
of diagnosis of fractures or osteonecrosis and at last visit for those without either outcome. 
There was a higher proportion of fractures and osteonecrosis among IV drug users and 
HCV coinfected persons. Persons with a bone outcome tended to have a lower current 
CD4 count than those without an event. Persons with osteonecrosis had significantly 
higher levels of triglycerides. There were no differences between participants with and 
without a bone outcome in terms of chronic kidney disease, estimated glomerular filtration 
rate (eGFR) and vitamin D levels (Table 1). 
    Among 11,820 included participants during 86,118 PYFU, 496 persons had 619 incident 
fractures (incidence rate [IR]/1,000 PYFU, 95% confidence interval [CI]: 7.2, 6.6-7.7) and 
73 persons developed 89 cases of osteonecrosis of the femoral head (IR: 1.0, 0.8-1.3) 
(Supplemental Figure 1).  
    Considering fractures with a known site, the most frequent were fractures of the leg, 
followed by arm, ribs and foot. 132 fractures (21.3%) were classified as osteoporotic 
(Supplemental Figure 2). At last visit, participants with osteoporotic fractures were more 
likely to be older, have sexually-acquired HIV and to come from North Europe compared to 
participants with other fractures, but had otherwise similar demographic and clinical 
characteristics (Supplemental Table 1). Information regarding fracture site could not be 
ascertained for 202 fractures (32.6%).  Participants with fractures of unknown sites were 
more likely to be female, to be ART naïve at study entry, have a prior AIDS diagnosis and 
have a higher current CD4 count when compared to participants with known fracture sites.  
    In analyses stratified by time-updated CD4 count, the crude incidence of fractures 
decreased as CD4 counts increased (P<0.0001). On the other hand, the incidence of 
osteonecrosis did not vary significantly across different CD4 count strata (P=0.055).   
    Univariate and multivariate associations between covariates and risk for fractures and 
osteonecrosis are detailed in supplemental Tables 2 and 3. After adjustment, an increased 
risk of incident fractures was independently associated with older age, lower BMI, IV drug 
use, HCV co-infection, prior fracture, prior osteonecrosis of the femoral head, a recent 
non-AIDS-defining malignancy and recent cardiovascular disease (Figure 1). Another 
independent predictor of fractures was origin, with participants from Northern and Central 
Europe at significantly increased risk (Supplemental Table 2). Race other than white and a 
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higher current CD4 count were associated with lower fracture risk (Figure 1). Findings 
were not substantially different between men and women (data not shown). 
    With respect to osteonecrosis of the femoral head, a prior history of osteonecrosis, 
fractures and AIDS-defining illnesses (both opportunistic infections and AIDS-defining 
cancers) was independently associated with increased risk (Figure 1). Race other than 
white and a higher baseline CD4 count were independently associated with a lower risk for 
osteonecrosis (Figure 1)    
    In univariate analyses, ever, current and cumulative exposure to TDF was associated 
with increased fracture risk. Crude incidence rates are depicted in Figure 2. Whether 
modelled as ever, current or cumulative, no association between exposure to any of the 
other investigated antiretrovirals and fracture risk was observed (data not shown). After 
adjustment (Figure 3), persons who had ever used TDF (adjusted incidence rate ratio 
[aIRR], 95% CI: 1.40, 1.15-1.70 p=0.0008) or who were currently receiving TDF (aIRR 
1.25, 1.05-1.49, p=0.012) had a significantly increased incidence of fractures. The 
association of fracture risk with cumulative exposure to TDF did not retain statistical 
significance after adjustment (aIRR 1.08, 0.94-1.25, per 5 years of additional exposure, 
p=0.27). In analyses restricted to osteoporotic fractures, no significant association was 
seen with ever, current or cumulative exposure to TDF (Figure 3).  
    In adjusted analyses to investigate incidence rate ratios of fractures for categories of 
current ART use stratified according to TDF and boosted protease inhibitor, we found no 
difference in fracture risk in those receiving TDF but not boosted protease inhibitor (aIRR, 
95% CI: 0.91, 0.71-1.18 p=0.49) and in those receiving boosted protease inhibitor but not 
TDF (aIRR, 95% CI: 0.87, 0.65-1.03 p=0.09) when compared to persons simultaneously 
receiving TDF and boosted protease inhibitor.  
    After adjustment, persons who had ever used didanosine, indinavir, saquinavir, ritonavir 
boosted lopinavir, or TDF, had increased incidence rates of osteonecrosis of the femoral 
head (Figure 4), although the confidence intervals were quite wide reflecting the lower 
number of outcomes. However, when these antiretrovirals were mutually adjusted for, 
there was no significant relationship between exposure to any of them and osteonecrosis 
risk (Figure 4), although all of them were associated with a non-significant increased risk.  
There was no association between cumulative exposure to any of these antiretrovirals and 
osteonecrosis. Current use of ritonavir boosted lopinavir or TDF was not associated with 
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an increased incidence of osteonecrosis of the femoral head. There were not sufficient 
data to examine current exposure to didanosine, indinavir or saquinavir as these 
antiretrovirals are no longer commonly used. Whether assessed as ever, current or 
cumulative, exposure to none of the other investigated antiretrovirals was associated with 
osteonecrosis of the femoral head.  
    Pneumocystis pneumonia was associated with both bone outcomes in univariate 
analyses (IRR, 95% CI: 1.35, 1.02-1.79 p= 0.039, for fractures; and 2.61, 1.41-4.83 
p=0.0022, for osteonecrosis); this association, however, was no longer significant after 
adjustment (adjusted IRR, 95% CI: 0.99, 0.72-1.36 p=0.94, for fractures; and 1.27, 0.63-
2.49 p=0.51, for osteonecrosis).      
 
Discussion 
    In a large international HIV cohort involving participants receiving standard of care, we 
report that fractures and osteonecrosis of the femoral head are common bone outcomes. 
The risk of fractures and osteonecrosis seems to be determined by combination of host 
factors, HIV-specific variables and co-morbidities. We demonstrated that past and current 
exposure to TDF, but no other antiretroviral, was independently associated with higher 
incidence of fractures. Persons who had ever used didanosine, indinavir, saquinavir, 
ritonavir boosted lopinavir, or TDF, had higher risk of osteonecrosis of the femoral head, 
but this association was no longer significant after mutual adjustment. 
    Consistent with previous reports, we found that older age [1,16], white race [1,16], lower 
current CD4 count [17,18], IV drug use [1,19] and HCV co-infection [1,19] were 
independent predictors of fracture risk. We found that history of prior osteonecrosis, a 
recent non AIDS-defining cancer and recent cardiovascular disease were also associated 
with subsequent risk of fracture. The association with cancer and cardiovascular disease 
may reflect bone loss caused by co-morbidity treatments such as chemotherapy. It is also 
possible that a shared pathophysiological mechanism may lead to an increased risk of 
fractures and co-morbidities during HIV infection [20].  
    Exposure to TDF was linked to an increased risk of fractures in our study. Although 
smaller studies failed to find this association [15,17], our results are in overall agreement 
with larger and more recent cohort studies [1,16]. The question as to how TDF directly 
causes bone loss remains unanswered. Proximal tubular toxicity leading to phosphate 
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wasting and enhanced bone turnover is a possible mechanism [21]. However, proximal 
tubular renal dysfunction and enhanced bone turnover do not necessarily coexist [22]. In 
our study, there was no difference in renal function, as measured by eGFR, between those 
with and without a bone event. This suggests that TDF-associated bone toxicity and 
nephrotoxicity may be determined by different mechanisms. However, we did not compare 
proteinuria, glycosuria and phosphaturia among participants with and without fractures and 
it is possible that proximal tubular dysfunction among those receiving TDF may have 
preceded measurable changes in eGFR.     
    Of note, we found that past and current exposure to TDF, but not cumulative exposure, 
was associated with a significantly increased risk of fractures. A possible explanation is the 
fact that decreases in bone mineral density and increases in markers of bone turnover are 
steepest in the first one or two years following ART initiation [5,6,23]. After a critical initial 
period, abnormalities in bone metabolism caused by ART may not be progressive [23]. 
Consistent with this, the risk of fractures was found to be highest during the first two years 
of ART [15] to then continue to increase less steeply. We found an aIRR for fracture risk of 
1.08 per 5 years of additional exposure to TDF. Although this was not statistically 
significant we cannot exclude the possibility of 8% yearly cumulative risk of fractures with 
TDF exposure.   
    The pathophysiology of osteonecrosis of the femoral head is poorly understood [24], but 
the primary mechanism is vascular occlusion leading to bone hypoxia and necrosis [25]. 
Increased inflammation and coagulation, as demonstrated by elevated levels of D-dimer 
and C-reactive protein, were also linked to osteonecrosis risk [26]. In accordance with 
other studies, we found that history of ADS-defining conditions and lower CD4 counts [27-
29] are associated with increased risk of osteonecrosis. White race and history of prior 
fractures and prior osteonecrosis were factors independently associated with incident 
osteonecrosis. These same factors predicted fracture risk; which may be potentially 
explained by a common mechanism underlying the excess risk of osteoporosis and 
osteonecrosis in the setting of HIV infection [30]. However, whereas osteoporotic fractures 
are the clinical manifestation of low bone mineral density, osteonecrosis has a different 
pathogenesis involving impaired circulation [25].   
    We found past exposure to didanosine, indinavir, saquinavir, ritonavir boosted lopinavir, 
or TDF to be independently associated with osteonecrosis risk. However, after mutual 
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adjustment, these associations were attenuated and became no longer significant. A 
possible association between protease inhibitors and osteonecrosis risk was reported in a 
meta-analysis of case-control studies [31]. Our study was more methodologically sound 
because we had detailed time-updated information on exposure to individual antiretrovirals 
and performed mutual adjustment. However, we cannot exclude the possibility that ART 
exposure may have a small effect on osteonecrosis risk. If this was the case, the effect of 
individual antiretrovirals may have been too weak to be identified concomitantly with other 
bone-active drugs [32]. 
    Our study had important limitations. First, we had no data on bone mineral density and 
bone events were not centrally adjudicated. Therefore, we could not confirm the 
osteoporotic nature of fractures. Information on anatomic sites was unavailable for a 
sizeable proportion of fractures. Magnetic resonance imaging was not systematically 
performed to diagnose osteonecrosis of the femoral head; the occurrence of bone events 
was confirmed during monitoring visits only. Second, we had no data on alcohol use and 
use of corticosteroids, megestrol acetate or testosterone. Exposure to these drugs has 
been previously reported in relation to risk of fractures and osteonecrosis [29,33,34]. We 
investigated previous history of Pneumocystis pneumonia as a proxy for corticosteroid 
exposure and found no significant association in adjusted analyses.  Third, ART evolves 
quickly and it is unclear whether our findings are generalizable to tenofovir alafenamide 
(TAF)-  or integrase inhibitor-based ART regimens.  
    To conclude, fractures and osteonecrosis of the femoral head are manifestations of 
bone disease among HIV positive persons receiving ARV treatment. Host factors, HIV-
specific variables and co-morbidities contribute to the risk of these bone events. Past and 
current exposure to TDF, but not cumulative exposure, is independently associated with 
fracture risk.  Our data supports cautious use of TDF among HIV positive persons at 
fracture risk initiating ART as recommended by current guidelines [35] and expert panels 
[36]. Individual antiretrovirals are not significantly associated with risk of osteonecrosis of 
the femoral head after mutual adjustment. However, we could not exclude a small effect of 
ART exposure on osteonecrosis risk. Larger studies are warranted to clarify this.           
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Figures 
Figure 1: Factors independently associated with fractures and osteonecrosis of the 
femoral head.  
aIRR: adjusted incidence rate ratio. Models adjusted for depicted covariates plus 
calendar year and region. Only covariates significant (p<0.1) in univariate analyses 
were included in multivariate models to avoid overfitting.  
1 not significant for osteonecrosis in univariate analysis and hence not included in 
multivariate model for osteonecrosis 
2 not significant for fractures in univariate analysis and hence not included in 
multivariate model for fractures 
  
Figure 2: Crude incidence of fractures. TDF use. 
CI: confidence interval, PYFU: person-years of follow up, TDF: tenofovir disoproxil 
fumarate. 
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Figure 3: Effect of TDF exposure on risk of any fracture and of osteoporotic 
fractures a. 
a grouped as fractures of the spine, arm, wrist and hip 
b adjusted for demographics, HIV-specific variables and co-morbidities. 
 
Figure 4: Relationship between antiretroviral drugs and osteonecrosis. 
ARV: antiretroviral, DDI: didanosine, IDV: indinavir, LPV/r: ritonavir boosted 
lopinavir, SQV: saquinavir, TDF : tenofovir disoproxil fumarate.   
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Table 1:  Characteristics at last visit for those with no bone event, or at last diagnosis of fracture or 
osteonecrosis 
Variable No bone event Fractures Osteonecrosis of 
the femoral head 
P-value* 
Overall 11266 (95.2) 496 (4.2) 73 (0.6)  
Demographics 
n(%)/Median (IQR) 
    
Male gender 8460 (75.4) 357 (72.1) 58 (76.5) 0.22 
Age (years) 49 (42,56) 50 (44,59) 47 (43,56) 0.0089 
HIV transmission group      
   MSM 4800 (42.6) 180 (36.4) 35 (47.9) 0.0032 
   Heterosexual 3475 (30.9) 150 (30.3) 17 (23.3)  
   IDU 2156 (19.1) 130 (26.3) 14 (23.3)  
White ethnicity 9702 (86.1) 445 (89.9) 68 (93.1) 0.013 
Asian 207 (1.8) 9 (1.6) 2 (2.7)  
Black 638 (5.7) 21 (4.2) 1 (1.4)  
Other 719 (6.4) 21 (4.2) 2 (2.7)  
Body Mass Index (Kg/m2)     
    ≤ 18 926 (9.3) 64 (13.9) 10 (14.9) 0.0006 
    18-30 4248 (42.8) 214 (46.4) 29 (43.3)  
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     >30 4760 (47.9) 183 (39.7) 28 (41.8)  
HIV-specific variables 
n(%)/Median (IQR) 
    
On ART 10857 (89.1) 486 (97.0) 73 (100) 0.20 
CD4 cells/mm
3
 540 (340,749) 450 (332,658) 468 (328,621) 0.0004 
Nadir CD4 cells/mm
3
 176 (72,290) 120 (50,230) 90 (28,168) <0.0001 
HIV RNA <500 cp/ml 10032 (89.1) 441 (89.1) 70 (95.9) 0.17 
Co-morbidities n(%) 
    
HCV positive 2805 (24.9) 157 (31.7) 18 (24.7) 0.012 
Current smoking 3248 (28.8) 188 (38.0) 31 (42.5) <0.0001 
Prior osteonecrosis 43 (0.4) 14 (2.8) 20 (27.4) <0.0001 
Prior fracture 202 (1.8) 79 (16.0) 6 (8.2) <0.0001 
Prior AIDS 3526 (31.6) 188 (38.0) 43 (58.9) < 0.0001 
Prior AIDS (not cancer) 3114 (27.6) 176 (35.6) 38 (52.1) <0.0001 
Prior AIDS (cancer) 743 (6.6) 30 (6.1) 14 (19.2) <0.0001 
Prior non-AIDS cancer  1570 (13.9) 80 (16.2) 11 (15.1) 0.37 
Prior cardiovascular disease 229 (2.0) 21 (4.2) 3 (4.1) <0.0001 
Recent AIDS event 
a
 217 (1.9) 8 (1.6) 0 (0) 0.43 
Recent AIDS (not cancer) 
a
 172 (1.5) 7 (1.4) 0 (0) 0.58 
Recent AIDS cancer 
a
 55 (0.5) 1 (0.2) 0 (0) 0.25 
Recent non-AIDS cancer 
a
 403 (3.6) 23 (4.7) 6 (8.2) 0.052 
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Recent cardiovascular 
disease 
a
 
10 (0.1) 4 (0.8) 0 (0) <0.0001 
Chronic kidney disease 
b
 583 (5.3) 26 (5.6) 5 (7.5) 0.71 
eGFR 
c
 mL/min/1.73 m
2
 
Median (IQR)  
95 (80,106) 96 (79,106) 94 (75,106) 0.58 
Vitamin D 
d
 ng/mL 
Median (IQR) 
37 (22,65) 35 (15,83) 31 (9,40) 0.26 
Total cholesterol mg/dL 
Median (IQR)e 
191 (162  -223) 193 (166 – 223) 196 (170 – 228) 0.43 
Triglycerides mg/dL 
Median (IQR)f 
136 (92 – 208) 139 (97 – 208) 181 (108 – 328) 0.0025 
*global p-values for comparing across the three groups 
(a) Occurring in the last 12 months prior to the diagnosis of fracture or osteonecrosis of the femoral head. 
(b) chronic kidney disease at any time before last visit or event date; defined as confirmed (> 3 months apart) 
eGFR < 60 for those with first eGFR > 60, or 25% decline where baseline eGFR< 60.  eGFRs were 
calculated using CKD-EPI formula. 
(c)  eGFR was available for 11536 (97.5%); 11003 (97.7%) for those with no events, 466 (94.1%) for those 
with any fracture and 67 (91.8%) for those with osteonecrosis of the femoral head (p<0.0001).  
(d)  Data available for 3291 (27.8%) overall, 3210 (28.5%) for those with no events, 71 (14.3%) for those with 
fractures and 10 (13.7%) of those with osteonecrosis of the femoral head (p<0.0001). 
(e) Data available for 11687 (98.9%) overall; 11122 (98.7%) for those with no events, 492 (99.4%) for those 
with fractures and 73 (100%) of those with osteonecrosis of the femoral head (p=0.26) 
(f) Data available for 11365 (96.2%) overall; 10813 (96.0%) for those with no events, 482 (97.4%) for those 
with fractures and 70 (95.9%) of those with osteonecrosis of the femoral head (p=0.26) 
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Supplemental Table 1: Participant characteristics at last visit: non-osteoporotic versus 
osteoporotic fractures 
    Non-osteoporotic Osteoporotic P-value  
Overall 486 (78.6) 132 (21.4)   
Characteristic  
n(%)/Median (IQR) 
   
Gender Male 357 (73.5) 91 (68.9) 0.30 
Age (years)   49 (44,59) 52 (46,60) 0.021 
HIV transmission 
group 
MSM 170 (35.0) 52 (39.4) 0.030 
  IV drug use 141 (29.0) 27 (20.5)   
  Heterosexual 131 (27.0) 47 (35.6)   
Race White 436 (89.7) 123 (93.2) 0.23 
Region North Europe 211 (43.4) 72 (54.6) 0.0006 
  Central and 
Eastern 
Europe 
47 (9.7) 22 (16.7)   
On ART    468 (96.3) 129 (97.7) 0.42 
CD4  cells/mm
3
 
  441 (311,663) 454 (340,651) 0.62 
Viral load < 500 
copies/mL 
  427 (87.9) 119 (90.2) 0.47 
HBV Pos 25 (5.1) 5 (3.8) 0.61  
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HCV Pos 166 (34.2) 39 (29.6) 0.57 
Recent AIDS a 7 (1.4) 4 (3.0) 0.22 
Chronic kidney 
disease b 
  28 (5.8) 3 (2.2) 0.10 
eGFR c   97 (80,106) 95 (77,100) 0.33 
Vitamin D d   33 (11,72) 34 (23,84) 0.42 
(a) in last 12 months prior to diagnosis of fractures  
(b) chronic kidney disease at any time before last visit or event date; defined as confirmed (> 3 
months apart) eGFR < 60 for those with first eGFR > 60, or 25% decline where baseline eGFR< 
60.  
(c) eGFR was available for 455 (93.6%) for those with non-osteoporotic fractures and 127 (96.2%) 
for those with osteoporotic fractures (p=0.26). eGFRs were calculated using CKD-EPI formula. 
(d) Data available for 64 (13.2%) for those with non-osteoporotic fractures and 15 (11.4%) for those 
with osteoporotic fractures (p=0.58).    
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Supplemental Table 2: Univariate and multivariate factors associated with any fracture 
  Univariate Multivariate 
  IRR 95% CI P IRR 95% CI P 
Age /10 yrs 1.42 1.31 – 1.54 <0.0001 1.39 1.26 – 1.53 <0.0001 
HIV transmission 
group 
IDU 1.75 1.39 – 2.14 <0.0001 1.58 1.18 – 2.12 0.0021 
 Other 1.00 - - 1.00 - - 
Race White 1.00 - - 1.00 - - 
 Other 0.67 0.50 – 0.90 0.0073 0.64 0.47 – 0.88 0.0056 
BMI <18 1.69 1.27 – 2.26 0.0004 1.51 1.14 – 1.99 0.0036 
 18-30 1.00 - - 1.00 - - 
 >30 0.90 0.73 – 1.10 0.30 0.91 0.74 – 1.11 0.36 
 unknown 0.65 0.44 – 0.98 0.039 0.79 0.52 – 1.18 0.25 
CD4* /doubling 0.73 0.64 – 0.83 <0.0001 0.80 0.69 – 0.92 0.0014 
Nadir CD4 /doubling 0.71 0.63 – 0.80 <0.0001 0.92 0.79 – 1.07 0.25 
Baseline <500 1.00 - - 1.00 - - 
Viral Load 500-100k 0.68 0.53 – 0.87 0.0019 0.84 0.66 – 1.08 0.17 
 >100k 1.06 0.70 – 1.60 0.78 1.05 0.71 – 1.55 0.81 
Region S 1.00 - - 1.00 - - 
 N 1.80 1.32 – 2.47 0.0003 1.83 1.32 – 2.52 0.0003 
 C 3.29 2.47 – 4.40 <0.0001 3.63 2.68 – 4.91 <0.0001 
 CE 1.58 1.12 – 2.22 0.0092 1.60 1.13 – 2.28 0.0087 
Year of follow up* <2006 1.00 - - 1.00 - - 
 07-09 1.58 1.22 – 2.04 0.0005 1.50 1.16 – 1.94 0.0020 
 10-12 1.75 1.36 – 2.25 <0.0001 1.56 1.20 – 2.02 0.0007 
 >2012 1.28 0.95 – 1.72 0.10 1.09 0.80 – 1.48 0.58 
HCV* Neg 1.00 - - 1.00 - - 
 Pos 1.70 1.39 – 2.09 <0.0001 1.59 1.20 – 2.11 0.0013 
 Unknown 0.68 0.45 – 1.03 0.068 0.81 0.53 – 1.22 0.31 
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Smoking Never 1.00 - - 1.00 - - 
 Current 1.28 1.01 – 1.61 0.040 1.09 0.86 – 1.38 0.47 
 Past 0.93 0.70 – 1.29 0.65 0.80 0.58 – 1.11 0.18 
 Unknown 0.90 0.70 – 1.15 0.38 0.72 0.57 – 0.92 0.0083 
 Arg 0.68 0.35 – 1.41 0.30 0.88 0.42 – 1.82 0.72 
Osteonecrosis* No 1.00 - - 1.00 - - 
Yes 4.69 2.95 – 7.46 <0.0001 3.19 1.91 – 5.31 <0.0001 
Prior 
Fracture 
No 1.00 - - 1.00 - - 
Yes 5.24 3.45 – 7.96 <0.0001 3.89 2.62 – 5.77 <0.0001 
AIDS (not 
cancer)* 
 1.46 1.20 – 1.77 <0.0001 1.13 0.92 – 1.38 0.25 
Recent non-
AIDS-defining 
malignancy* 
 3.10 2.11 – 4.57 <0.0001 1.88 1.26 – 2.80 0.0018 
Recent 
cardiovascular 
disease* 
 9.56 3.68 – 
24.82 
<0.0001 6.03 2.28 – 15.95 0.0003 
All factors fixed at baseline, except *, which were time-updated 
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Supplemental Table 3: Univariate and multivariate factors associated with osteonecrosis of the 
femoral head 
  Univariate Multivariate 
  IRR 95% CI P IRR 95% CI P 
Age /10 yrs 1.19 0.99 – 1.43 0.068 1.07 0.87 – 1.31 0.54 
Race White 1.00 - - 1.00 - - 
 Other 0.38 0.15 – 0.95 0.038 0.28 0.11 – 0.76 0.012 
Nadir CD4 /doubling 0.52 0.36 – 0.75 0.0005 0.71 0.51 – 1.01 0.054 
Prior 
osteonecrosis 
No 1.00 - - 1.00 - - 
Yes 20.82 10.32 – 
41.99 
<0.0001 14.95 6.96 – 32.15 <0.0001 
Prior fracture* No 1.00 - - 1.00 - - 
 Yes 4.26 2.13 – 8.50 <0.0001 3.12 1.50 – 6.49 0.0023 
AIDS (not 
cancer)* 
 2.92 1.78 – 4.80 <0.0001 2.13 1.27 – 3.57 0.0043 
AIDS-defining 
cancer* 
 3.57 1.96 – 6.50 <0.0001 2.69 1.48 – 4.89 0.0012 
Non-AIDS-
defining 
malignancies* 
 2.00 1.03 – 3.91 0.042 1.33 0.65 – 2.69 0.43 
All factors fixed at baseline, except *, which were time-updated 
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